Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study
- 10 December 2023
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30779
Abstract
Background and objectives: Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children historically associated with significant morbidity and mortality. This study was conducted to determine first‐line therapy in the absence of available prospective clinical trials.Methods: Patients from 17 institutions diagnosed with KHE/TA between 2005 and 2020 with more than 6 months of follow‐up were included. Response rates to sirolimus and vincristine were compared at 3 and 6 months. Durability of response and response to other treatment modalities were also evaluated.Results: Of 159 unique KHE/TA subjects, Kasabach–Merritt phenomenon (KMP) was present in 64 (40.3%), and only two patients were deceased (1.3%). Over 60% (n = 96) demonstrated treatment response at 3 months, and more than 70% (n = 114) by 6 months (no significant difference across groups). The vincristine group had higher radiologic response at 3 months compared to sirolimus (72.7% vs. 20%, p = .03), but there were no differences between these groups at 6 months. There were no differences in rates of recurrent or progressive disease between vincristine and sirolimus.Conclusions: In this large, multicenter cohort of 159 patients with KHE/TA, rates of KMP were consistent with historical literature, but the mortality rate (1.3%) was much lower. Overall treatment response rates were high (>70%), and there was no significant difference in treatment response or durability of disease comparing sirolimus to vincristine. Our results support individualized treatment decision plans depending on clinical scenario and patient/physician preferences. Response criteria and response rates reported here will be useful for guiding future treatment protocols for vascular tumors.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- Treatment of kaposiform hemangioendothelioma and tufted angiomaInternational Journal of Cancer, 2016
- Recent advances in the pathobiology and management of Kasabach–Merritt phenomenonBritish Journal of Haematology, 2015
- Kaposiform Hemangioendothelioma: Atypical Features and Risks of Kasabach-Merritt Phenomenon in 107 ReferralsThe Journal of Pediatrics, 2013
- Sirolimus for the treatment of complicated vascular anomalies in childrenPediatric Blood & Cancer, 2011
- Treatment of childhood kaposiform hemangioendothelioma with sirolimusPediatric Blood & Cancer, 2010
- Kasabach-Merritt PhenomenonJournal of Pediatric Hematology/Oncology, 2009
- The Role of the Hematologist/Oncologist in the Care of Patients with Vascular AnomaliesPediatric Clinics of North America, 2008
- Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach–Merritt phenomenon using four‐drug regimenPediatric Blood & Cancer, 2006
- Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenonJournal of the American Academy of Dermatology, 2005
- CAPILLARY HEMANGIOMA WITH EXTENSIVE PURPURAA.M.A. American Journal of Diseases of Children, 1940